Navigation Links
Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium

MARSEILLE, France, Dec. 21 /PRNewswire/ -- Ipsogen SA (Alternext: ALIPS) today announced that a new study confirming the pivotal role of tumor grade in chemotherapy prescription has been presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), December 9-13, 2009.

The study was conducted at Institut Paoli Calmettes (IPC) Cancer Centre, Marseille, France. Using the centre database and a classification tree method, it retrospectively examined the tumor and patient characteristics driving prescription of adjuvant chemotherapy for 5854 early stage node negative (M-/N-), invasive breast cancer (IBC) patients treated between 1999 and 2005.

The study results indicate that tumor grade is the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size. Hierarchy of factors driving chemotherapy decision is remarkably stable over time, despite the progressive availability of new pathologic indicators over time.

"These new findings further support the value of Genomic Grade -a tool to refine tumor grading by resolving intermediate histologic grade 2 tumors in which indication of chemotherapy is a clinical challenge -- for treatment decision making. Integrated in currently validated treatment algorithms using tumor grade, the Genomic Grade could contribute to a more individualized chemotherapy strategy in Invasive Breast Cancer," comments Helene Peyro-Saint-Paul, Ipsogen Chief Medical Officer.

The study was presented at Poster Session 2, Friday, Dec 11, 2009, abstract # 2089:

Title: Real-life implementation of treatment guidelines for adjuvant chemotherapy in invasive breast cancer: retrospective analysis of a large single centre 10-year database.

Jean-Marie Boher, Jean-Marc Extra, Jacques Camerlo, Carole Tarpin, Emmanuelle Charaffe-Jauffret, Eric Lambaudie, Agnes Tallet, Helene Peyro-Saint-Paul, Patrice Viens


Ipsogen develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path. With more than 70 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. As for leukemia, Ipsogen's goal is to provide diagnostic information that was not available until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to the development of 'companion diagnostic' tests.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in molecular profiling of cancers. It continues its efforts to identify develop and commercialize diagnostic tests that will become standard references and will have a significant impact on patients, medical professionals and society. Ipsogen employed 70 people as of June 30, 2009. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit:


Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
2. Dyadic International Extends Collaboration With The Scripps Research Institute
4. Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards
5. Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases
6. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
7. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
8. Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus
9. Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes
10. Schulman Associates IRB Establishes an Institutional Review Board in Canada
11. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
Post Your Comments:
(Date:10/12/2015)... ... 2015 , ... Dr. Carl Peck, MD, Chairman of NDA ... a Premier Expert consultant. NDA Partners Premier Experts are top tier consultants ... company's clients. Premier Experts collaborate to design and implement critical solutions to ...
(Date:10/11/2015)... ... October 11, 2015 , ... Intelligent Implant ... officially launched and multiple surgeries have been completed with this new posterior thoracolumbar ... Neuroscience & Spine Center of the Carolinas. The Revolution™ Spinal System pioneers ...
(Date:10/9/2015)... , Oct. 9, 2015 On October ... the Congressional Record her statement recognizing the third annual ... 11-17. IPAW is sponsored by the Plasma Protein ... is designed to:   , Raise global awareness ... plasma donors in saving and improving lives , ...
(Date:10/9/2015)...  DePuy Synthes Trauma* announced today the U.S. launch ... Technology**, the only pre-hydrated demineralized cancellous bone tissue matrix ... ankle, hand and wrist), including fusion, and for filling ... 2015 Orthopaedic Trauma Association (OTA) Annual Meeting. ... bone growth) and osteoinductive 2,3 (stimulates new bone ...
Breaking Biology Technology:
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to be ... its product to market. The official announcement was recently made ... event in San Francisco , where ... powered by IBM Watson. "It is both an ... 100 companies to bring to market the cognitive power of ...
(Date:9/28/2015)...  The monitoring of vital signs, such as ... an essential component of patient assessment. Changes in ... a patient,s condition. However, in general care areas ... during routine observation rounds only once every four ... these observation rounds, the warning signs can go ...
(Date:9/28/2015)... , September 28, 2015 According ... (Hardware & Software), Product (Scanner & Others), Application (Access ... Defense, & Others) & Geography Global - Forecast to ... to reach USD 3627.90 Million by 2020, at a ... Browse 65 market data T ables and ...
Breaking Biology News(10 mins):